Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01652079
Title CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.